256 Newsroom — Uganda's Digital News Infrastructure
Business

Roche inks $1.53B deal for Simcere’s B-cell-targeting antibody - Fierce Biotech

Published by FierceBiotech By Marissa Russo · 1 September 2026 at 17:41
Share
Roche inks $1.53B deal for Simcere’s B-cell-targeting antibody - Fierce Biotech
Image · FierceBiotech

What the report says

Roche is paying oncology-focused Simcere Zaiming $75 million upfront for global rights to a preclinical trispecific antibody targeting B-cell-mediated diseases. | Roche is paying oncology-focused Simcere Zaiming $75 million upfront for global rights to a prec…

Read the full report at FierceBiotech →

Loading debate for this article…

Other publishers covering this story

No additional verified coverage is currently clustered with this report.

More stories by this journalist

Other publications from this journalist — open any story without leaving the article page.

No other published stories from this publisher yet.

Related reporting

256 Newsroom Why World Vision is exiting Rakai’s Kyarurangira after 20 years - Daily MonitorDaily Monitor Uganda’s informal economy seeks strength in numbersThe Observer 256 Newsroom Gen Saleh Calls for Review of Caged-Fishing and Coffee-Farming Projects - ChimpReportsChimpReports 256 Newsroom King Oyo’s legacy: How a boy monarch redefined Uganda’s cultural resilience - monitor.co.ugDaily Monitor Gen. Saleh Calls For Review Of Caged-Fishing And Coffee-Farming ProjectsWatchdog Uganda Rubanda Launches Shs40m Road Project to Boost Farm-to-Market AccessNile Post